Treatment approaches for primary CNS lymphomas

被引：22

作者：

Carrabba, Matteo G. ^{[1
,2
]}

Reni, Michele

Foppoli, Marco ^{[1
]}

Chiara, Anna ^{[3
]}

Franzin, Alberto ^{[4
]}

Politi, Letterio Salvatore ^{[5
]}

Villa, Eugenio

Ciceri, Fabio ^{[2
]}

Ferreri, Andres J. M. ^{[1
]}

机构：

[1] Ist Sci San Raffaele, Unit Lymphoid Malignancies, Med Oncol Unit, Dept Oncol, I-20132 Milan, Italy

[2] Ist Sci San Raffaele, Haematol & Bone Marrow Transplantat Unit, Dept Oncol, I-20132 Milan, Italy

[3] Ist Sci San Raffaele, Radiotherapy Unit, Dept Oncol, I-20132 Milan, Italy

[4] Ist Sci San Raffaele, Dept Head & Neck, Neurosurg Unit, I-20132 Milan, Italy

[5] Ist Sci San Raffaele, Dept Head & Neck, Neuroradiol Unit, I-20132 Milan, Italy

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 08期

关键词：

CENTRAL-NERVOUS-SYSTEM; HIGH-DOSE METHOTREXATE; STEM-CELL TRANSPLANTATION; WHOLE-BRAIN RADIOTHERAPY; NON-HODGKINS-LYMPHOMA; COMBINED-MODALITY THERAPY; RECURRENT PRIMARY CNS; PHASE-II MULTICENTER; INTRAOCULAR LYMPHOMA; IMMUNOCOMPETENT PATIENTS;

D O I：

10.1517/14656561003767456

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered in this review: This review describes conventional and investigational treatments for PCNSL and focuses on the main questions for future clinical trials. PubMed and the authors' own files were utilized for references search. The terms 'PCNSL', 'primary AND CNS lymphoma', and 'CNS AND lymphoma' were used for PubMed queries. All papers published in English before November 2009 were considered. What the reader will gain: This review illustrates how the paradigm for PCNSL treatment changed during the 1990s from radiotherapy alone to the establishment of high-dose methotrexate-cytarabine combination as standard approach. We present promising data from Phase II studies and discuss questions for randomized trials. Finally, we offer a 5-year scenario for the management of PCNSL. Take-home message: The methotrexate-cytarabine combination should currently be considered as the reference treatment for PCNSL. Well-designed randomized trials and biological studies deriving from the use of novel technologies will be crucial to further improve outcome in these patients.

引用

页码：1263 / 1276

页数：14

共 79 条

[1] Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis [J].